| abstract |
Pharmacologically-valuable 3,4-(bis-substituted)-1,2,5-oxdiazole 2-oxides of formula I <IMAGE> (I) [wherein R denotes -NHR1, -NR2R3, -NHR4OR2, -NHR5COR6 or <IMAGE> R1 denotes alkyl having from 1 to 6 C atoms or cycloalkyl having 4 to 7 ring C atoms, R2 and R3 denote alkyl having from 1 to 4 C atoms, R4 denotes an alkylene radical of the formula -CnH2n-(wherein n denotes 2, 3 or 4), R5 denotes an alkylene radical of the formula -CmH2m- (wherein m denotes 1, 2 or 3), R6 denotes -OR2, -NHR1, -NR2R3 or -NH2, X denotes -(CH2)p-, -(CH2)2-O-(CH2)2- or <IMAGE> and p is 4, 5 of 6] and their pharmacologically-acceptable acid-addition compounds are prepared by elimination of hydrogen chloride from a hydroxamoyl chloride of the formula R-CO-C(Cl)=NOH (II) and dimerization. If desired, the resulting reaction product is subsequently converted into an acid-addition compound. The compounds and pharmaceutical preparations thereof are useful for treating and for prophylaxis of cardiovascular diseases. |